<DOC>
	<DOCNO>NCT00830076</DOCNO>
	<brief_summary>This study assess effect sitagliptin metformin alone co-administration incretin hormone concentration patient Type 2 diabetes .</brief_summary>
	<brief_title>A Study Effects Co-Administration Sitagliptin ( MK-0431 ) Metformin Incretin Hormone Concentrations ( MK-0431-110 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Female subject must negative pregnancy test Subject type 2 diabetes currently receive treatment oral AHA agent , receive treatment 3 month prior study , and/or receive 4 total week treatment oral AHA agent 12 18 month prior study Subject nonsmoker smoke and/or use nicotine least 6 month Subject history stroke , seizure , major neurological disorder Female subject breastfeed Subject refrain use prescription nonprescription drug begin 2 week prior first dose study drug Subject consume 3 alcoholic beverage per day Subject consume 6 caffeinated beverage per day Subject major surgery , donate lose 1 unit blood within 4 week screen Subject history cancer , except certain skin cervical cancer cancer treat 10 year prior screen Subject history multiple and/or severe allergy intolerance drug food</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>